A detailed history of Securian Asset Management, Inc transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Securian Asset Management, Inc holds 9,666 shares of ARWR stock, worth $189,743. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,666
Previous 9,905 2.41%
Holding current value
$189,743
Previous $257,000 27.24%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$19.36 - $29.54 $4,627 - $7,060
-239 Reduced 2.41%
9,666 $187,000
Q2 2024

Jul 15, 2024

SELL
$21.87 - $28.24 $4,264 - $5,506
-195 Reduced 1.93%
9,905 $257,000
Q1 2024

Apr 26, 2024

BUY
$27.21 - $39.48 $30,502 - $44,257
1,121 Added 12.48%
10,100 $288,000
Q4 2023

Feb 08, 2024

SELL
$21.2 - $31.03 $2,120 - $3,103
-100 Reduced 1.1%
8,979 $274,000
Q3 2023

Oct 30, 2023

SELL
$26.2 - $36.08 $11,632 - $16,019
-444 Reduced 4.66%
9,079 $243,000
Q2 2023

Aug 07, 2023

SELL
$25.16 - $41.38 $8,579 - $14,110
-341 Reduced 3.46%
9,523 $339,000
Q1 2023

Apr 27, 2023

BUY
$23.68 - $38.51 $5,328 - $8,664
225 Added 2.33%
9,864 $250,000
Q2 2022

Aug 04, 2022

BUY
$27.79 - $50.61 $4,918 - $8,957
177 Added 1.87%
9,639 $339,000
Q1 2022

May 03, 2022

BUY
$39.62 - $69.97 $4,437 - $7,836
112 Added 1.2%
9,462 $435,000
Q3 2021

Nov 08, 2021

SELL
$58.38 - $84.96 $12,551 - $18,266
-215 Reduced 2.25%
9,350 $584,000
Q2 2021

Aug 10, 2021

SELL
$62.15 - $90.32 $10,876 - $15,805
-175 Reduced 1.8%
9,565 $792,000
Q4 2020

Feb 08, 2021

SELL
$43.82 - $85.37 $8,501 - $16,561
-194 Reduced 1.95%
9,740 $747,000
Q3 2020

Nov 04, 2020

SELL
$33.21 - $51.27 $11,391 - $17,585
-343 Reduced 3.34%
9,934 $428,000
Q4 2019

Feb 04, 2020

BUY
$28.14 - $73.01 $289,194 - $750,323
10,277 New
10,277 $652,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.08B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Securian Asset Management, Inc Portfolio

Follow Securian Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Securian Asset Management, Inc with notifications on news.